Here’s Why Biocept Share Price Rallied 36.2% Higher Today

Shares of Biocept (NASDAQ: BIOC) a US provider of molecular technologies to clinicians today rallied 36.2% high rafter the company unveiled an agreement with Aegea Biotechnologies to develop a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus.

The COVID-19 PCR assay is built on the core Switch-Blocker technology developed by Biocept and used in its suite of ultra-sensitive oncology-focused assays.

Michael Nall, President and CEO of Biocept commented that: “This project further expands on Biocept’s initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19.”

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Stella M. Sung, Ph.D., Chief Business Officer of Aegea explained that: “Working with Biocept better enables the potential rapid development of this new PCR-based COVID-19 assay. Biocept has successfully utilized Switch-Blocker technology to test for rare oncology-related genetic mutations in tens of thousands of clinical samples.”

Biocept share price

• Trade Biocept shares with the best stock brokers
• Learn how to trade stocks on this free demo account